Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

COPD drug showdown: taneasy vs fluimucil in new study

NCT ID NCT06828120

Disease control Sponsor: Bun Yao Biotechnology Co., Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed Phase 4 trial tested two mucus-thinning drugs, Taneasy and Fluimucil, in 45 adults with COPD. Participants took the granules twice daily for 14 days. The study measured how well the drugs helped clear mucus and improve breathing, using the COPD Assessment Test (CAT) score. The goal was to see if Taneasy works as well as Fluimucil for symptom relief.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Taneasy (acetylcysteine) granules and Fluimucil (acetylcysteine) granules
What this could lead to
If this works, it could show that Taneasy is as safe and effective as Fluimucil for helping COPD patients clear mucus and breathe easier.
What could go wrong
This is a small, completed Phase 4 trial with only 45 participants. Results may not apply to all COPD patients, and the 14-day treatment period is short.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

45 people

The number who actually took part.

Started

Feb 2025

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects aged older than 20\~75 years old. * Able to sign informed consent prior to the study. * The appearance of sputum and the difficulty of expectoration are both at level 2 or above. Exclusion Criteria: * Subjects with known hypersensitivity to Acetylcysteine preparations. * Subjects with other serious medical diseases that are judged by the attending physician to affect the evaluation results (such as: tuberculosis, pneumonia, bronchial asthma, bronchiectasis, cor pulmonale, lung cancer, acute myocardial infarction, acute hepatitis, renal failure, etc.) * Pregnancy or breast-feeding woman. * Female subjects or their sexual partners do not use contraception during the trial. * Joining any drug clinical trial within 3 months prior to dosing. * Investigator considered to be inappropriate for enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD (chronic obstructive pulmonary disease) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD (chronic obstructive pulmonary disease)

Contacts and locations

Locations

  • Taipei Veterans General Hospital

    Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.